Lyla Systems

Cover Block

Attribute	Value
Company Name	Lyla Systems
Tagline	Direct alpha particle measurement for radiopharma QC
Headquarters	Delft, Netherlands
Founded	2023
Stage	Pre-Seed
Business Model	B2B
Industry	Healthtech
Technology	Hardware
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	Undisclosed

Links

• Website: https://lyla.systems/
• LinkedIn: https://www.linkedin.com/in/ernstvdwal/

The Short Version

Lyla Systems is developing specialized hardware to solve a critical measurement bottleneck in the production of next-generation radiopharmaceutical cancer therapies [Yes!Delft]. The company emerged in 2023 from the research ecosystem at TU Delft, with co-founders Ernst van der Wal, Kas Hogeboom, and Bauke van Gameren bringing together physics research, hardware engineering, and software development expertise [Yes!Delft] [LinkedIn]. Its proposed system aims to measure alpha particles directly and in real-time during quality control, a claimed improvement over traditional scintillator-based methods [Yes!Delft].

Capitalization is limited to an undisclosed pre-seed round led by Graduate Entrepreneur [Graduate.nl]. The business model targets radiopharmaceutical manufacturers. For investors, the next 12-18 months will be defined by the transition from prototype to a validated instrument, the securing of initial pilot partnerships, and the ability to attract follow-on capital.

Data Accuracy: YELLOW -- Core company description and funding event corroborated by multiple Dutch ecosystem sources; specific product claims and team details are sourced from a single incubator profile.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Hardware
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Undisclosed

The Company in Brief

Lyla Systems was founded in 2023 in Delft, Netherlands, as a hardware-focused medtech startup emerging from the local research ecosystem [PitchBook]. The company's founding narrative centers on applying novel physics-based measurement to a specific bottleneck in modern cancer therapy development: quality control for radiopharmaceuticals [Yes!Delft].

The founding team consists of three co-founders. Ernst van der Wal is described as a creative engineer with an educational background from TU Delft [LinkedIn] [Yes!Delft]. His co-founders, Bauke van Gameren and Kas Hogeboom, contribute software and business expertise, respectively [RocketReach] [Yes!Delft]. The company's early development was supported by the YES!Delft incubator [Yes!Delft].

A key early milestone was securing a pre-seed investment from Graduate Entrepreneur, though the amount and specific date of this round are not publicly disclosed [Graduate.nl].

Data Accuracy: YELLOW -- Core founding facts confirmed by PitchBook and incubator profile; team details from LinkedIn and secondary aggregators; funding event announced but details are limited.

What They Have Built

Lyla Systems is developing a hardware and software system designed to measure alpha particles directly during the quality control process for radiopharmaceuticals [Yes!Delft]. The company's public positioning frames this as a technical improvement over established methods, which it claims are prone to inaccuracies and blind spots.

The core product claim is that direct measurement provides superior accuracy for ensuring the potency and safety of next-generation cancer treatments [Yes!Delft]. No public specifications, performance benchmarks, or images of a working prototype are available for independent verification.

Data Accuracy: YELLOW -- Product claims are sourced from company-affiliated press; no independent technical validation or detailed specifications are publicly available.

Market Research and Opportunity

Quality control in radiopharmaceutical manufacturing is a niche but critical bottleneck, gaining urgency as targeted alpha therapies progress from clinical trials toward commercial production.

The market Lyla Systems targets is defined by the production and quality assurance of radiopharmaceuticals, particularly those using alpha-emitting isotopes like Actinium-225 or Lead-212. The global radiopharmaceuticals market is large and growing, with one widely cited report from Grand View Research valuing it at $7.7 billion in 2023 and projecting a compound annual growth rate (CAGR) of 9.5% through 2030 [Grand View Research, 2024].

Demand is driven by the clinical pipeline. Over a dozen TAT candidates are in mid-to-late-stage clinical trials. Current scintillator-based detection systems are described by Lyla as having accuracy limitations and "blind spots" [Yes!Delft].

Metric	Value
Global Radiopharmaceuticals Market (2023)	7.7 $B
Projected CAGR (2024-2030)	9.5 %

Data Accuracy: YELLOW -- Market sizing from a single third-party report; segment-specific sizing for alpha QC hardware is not publicly available.

Who Else Is Fighting for This

Lyla Systems enters a specialized hardware niche where competition is defined by large, diversified incumbents.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Lyla Systems	Direct alpha particle measurement hardware/software for radiopharma QC	Pre-seed; Graduate Entrepreneur [Graduate.nl]	Claims superior accuracy and fewer blind spots vs. scintillator-based methods [Yes!Delft]	[PUBLIC]
Eckert & Ziegler	Diversified provider of isotopes, radiopharma equipment, and services	Public company (ETR:EUZ)	Full-service, vertically integrated supply chain for nuclear medicine	[PUBLIC]
Elysia-Raytest	Manufacturer of radiation measurement and QC equipment	Private, established (founded 1990)	Broad portfolio for radiopharmacy	[PUBLIC]
Alpha Spectra, Inc.	Developer of alpha spectroscopy systems for nuclear measurements	Private, established	Focus on high-resolution alpha spectroscopy	[PUBLIC]

Data Accuracy: YELLOW -- Competitor identification is public, but Lyla's differentiation claims are sourced solely from company-associated channels without independent verification.

Opportunity

If Lyla Systems executes, the prize is a foundational role in the quality control of a new generation of targeted cancer therapies. The headline opportunity is to become the standard for direct alpha measurement in radiopharmaceutical quality control.

Scenario	What happens	Catalyst	Why it's plausible
The Delft Standard	Lyla's system is adopted as the preferred QC tool within the dense Dutch and European radiopharma ecosystem.	A partnership with a major European nuclear research facility or a contract with a local radiopharma producer.	The founders emerged from the TU Delft research environment via the YES!Delft incubator [Yes!Delft].
The Platform Pivot	The core alpha measurement hardware becomes a module within a broader, software-driven QC and data management platform.	The release of a software suite that integrates dose calibration, batch record-keeping, and regulatory reporting.	The founding team explicitly combines hardware and software expertise [Yes!Delft].

Data Accuracy: YELLOW -- Opportunity analysis is based on cited product claims and market context; specific growth catalysts and comparables are extrapolated from the available landscape.

Sources

1. [Yes!Delft] Lyla: Quality control for the next generation of cancer treatment | https://yesdelft.com/stories/lyla-quality-control-for-the-next-generation-of-cancer-treatment/
2. [Graduate.nl] New pre-seed investment: LYLA | https://www.graduate.nl/insights/new-pre-seed-investment-lyla
3. [PitchBook] Lyla Systems 2025 Company Profile: Valuation, Funding & Investors | PitchBook | https://pitchbook.com/profiles/company/749220-94
4. [LinkedIn] Ernst van der Wal - Lyla | LinkedIn | https://www.linkedin.com/in/ernstvdwal/
5. [RocketReach] Bauke van Gameren Email & Phone Number | LYLA Co-founder and Software lead Contact Information | https://rocketreach.co/bauke-van-gameren-email_9152128
6. [Grand View Research, 2024] Global Radiopharmaceuticals Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/radiopharmaceuticals-market